bluuebunny/crossref_metadata_2025_split huggingface dataset:
384. NEOADJUVANT ANLOTINIB COMBINED WITH PENPULIMAB FOR RESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC): A PROSPECTIVE, SINGLE-ARM, PHASE II TRIAL
Authors: Yang YuShang , Liu Yixin , Chen Yueyun , Chen Longqi 
Published: September 2024

Abstract

Background
Neoadjuvant chemoradiation therapy followed by radical surgery has been extensively recommended for locally advanced esophageal squamous cell carcinoma (ESCC). However, toxicities and challenges to the subsequent surgery limit its wide clinical application. Immune checkpoint inhibitors combined with antiangiogenesis have synergistic effects and have shown good therapeutic effects in previous studies, as well as fewer side effects. Here, we tested a novel combination of anlotinib (an antiangiogeneic kinase inhibitor) and penpulimab (an anti-PD-1 antibody), without the use of radio- or chemo-therapy, for the neoadjuvant therapy of locally advanced ESCC.

Methods
In this prospective, single-arm, phase II clinical trial (ChiCTR2200064848), patients with resectable locally advanced ESCC (clinical stage III-IVa) were recruited. The study was designed using a two-stage minimax approach. The planned sample size was 40 patients would provide 80% power at a one-sided alpha error of 5%, threshold pathological complete response (pCR) of 16% and expected pCR of 30%. Here, the first-stage data was included. Notably, 85% (22/25) enrolled patients had medical contraindications (including cardiopulmonary diseases or other underlying medical conditions, along with poor nutritional status and so on). Patients received neoadjuvant therapy with anlotinib (8 mg, po, D1-14, Q3W) combined with penpulimab (200 mg, ivgtt, Q3W) for 2 cycles. Six to eight weeks later, patients underwent radical surgery after exclusion of contraindications. The primary endpoint was pathologic complete response (pCR) rate. Secondary endpoints included tumor regression grade (TRG), R0 resection rate, objective response rate (ORR) and safety profile.

Results
From Jan 2023 to Sep 2023, 25 patients (19 males and 6 females) were enrolled with a median age of 67 years (range: 50-74). All patients were available for efficacy assessment and 16 were evaluable for the primary end point. The rest of the patients are waiting for surgery. As of 15 Sep, 2023, 19 patients underwent esophagectomy and R0 resection rate was 87.5%. The pCR rate was 18.8% (3/16) and 31.3% of patients had a major pathologic response (MPR). The ORR and DCR were 48.0% and 96.0%, respectively. 84.0% of patients experienced grade 1-2 treatment-related adverse events (TRAEs), 3 (12.0%) patients experienced grade 3 TRAEs (2 elevated blood pressure and 1 elevation of liver enzymes). The safety profile revealed that the most common TRAEs (≥10%) included hypertension (28.0%), hand-foot syndrome (20%), fatigue (20%), abdominal pain (12%), toothache (12%).

Conclusions
The preliminary results of this study show promising safety and efficacy of anlotinib combined with penpulimab as neoadjuvant for patients with ESCC, especially for patients not suitable for neoadjuvant chemoradiation or chemotherapy. More ESCC patients would be recruited in the future.
387. VALIDATION OF PROMARKERESO, A DIAGNOSTIC BLOOD TEST TO IDENTIFY ESOPHAGEAL ADENOCARCINOMA
Authors: Peters Kirsten , Bringans Scott , Wang Iris , Duong Marisa N , Dhamrait Gursimran , Lipscombe Richard J 
Published: September 2024

Abstract

Background
Esophageal adenocarcinoma (EAC) has become the predominant type of esophageal cancer in Western countries. Early diagnosis and intervention of EAC significantly reduces the disease mortality. A previous study identified a panel of novel serum glycoprotein biomarkers that were associated with EAC, enabling the development of a prototype diagnostic blood test, PromarkerEso. The current study aimed to validate PromarkerEso in an independent cohort of patients with EAC.

Methods
Blood samples from an independent cohort of 165 participants (n=99 negative controls, n=66 diagnosed with EAC) were analyzed. Five candidate biomarkers were measured after lectin pulldown using a targeted mass spectrometry assay. Model performance was assessed by the area under the receiver operating characteristics curve (AUC-ROC) with sensitivity and specificity determined.

Results
After adjusting for clinical variables, diagnostic models showed good discrimination to distinguish participants with EAC from negative control participants.

Conclusions
This study validates a panel of serum glycoprotein biomarkers for the diagnosis of EAC. These biomarkers have potential utility as a simple blood test, PromarkerEso, that could be used for screening EAC in a large population.
390. CONTINUED IMPLICATIONS OF THE COVID-19 PANDEMIC ENVIRONMENT ON ESOPHAGEAL CANCER CHARACTERISTICS AND TREATMENT IN THE UNITED STATES
Authors: Stuart Christina , Bronsert Michael , Mott Nicole , Rodriguez-Franco Salvador , Gleisner Ana , Mungo Benedetto , Randhawa Simran , David Elizabeth , Mitchell John , McCarter Martin , Meguid Robert 
Published: September 2024

Abstract

Background
The COVID-19 pandemic significantly impacted the stage of presentation and subsequent therapies for patients who were diagnosed with esophageal cancer during the first pandemic year. We aimed to assess for continued implications of the altered healthcare landscape on esophageal cancer presentation and treatment in the second year of the pandemic.

Methods
This was a retrospective review of the United States National Cancer Database (2019-2021). Demographic, cancer-related and treatment variables were compared between patients diagnosed in the pre-pandemic year (2019), pandemic year one (2020) and pandemic year two (2021). Multivariate logistic regression was performed to control for the impact of demographics on oncologic variables, and then for the impact of oncologic variables on treatment modalities and outcomes.

Results
Of 42,807 esophageal cancer cases, 15,127 (35.3%) were pre-pandemic, 13,975 (32.7%) were pandemic year 1, and 13,705 (32.0%) were pandemic year two. There were significant differences in the distribution of clinical stage at presentation by year (p=0.0001), see figure, suggesting more advanced stage presentation throughout the pandemic. Compared to the pre-pandemic year, patients diagnosed in pandemic year two had risk-adjusted increases in time to first course treatment (incidence rate ratio 1.057 [95% confidence interval [1.036–1.078]), to radiation (1.029 [1.008–1.050]), and to systemic therapy (1.035 [1.018–1.051]). Additionally, when compared to pandemic year one, patients in pandemic year two continued to experience risk-adjusted increases in time to first course therapy (1.084 [1.063–1.106]), to surgery (1.049 [1.000–1.097]), to radiation (1.046 [1.024–1.068]) and to systemic therapy (1.060 [1.043–1.077]).

Conclusions
Compared to the pre-pandemic year, patients diagnosed with esophageal cancer in in the U.S. during pandemic year two continued to experience delays to treatment including delays to first course therapy, including delays to surgery, radiation and systemic therapy. The treatment characteristics of esophageal cancer have not returned to pre-pandemic baseline in the United States possibly due to compounding delays to diagnosis and treatment and a growing back log of cases.
403. ROBOTIC-ASSISTED IVOR LEWIS ESOPHAGECTOMY COMPARED TO CONVENTIONAL MINIMALLY INVASIVE ESOPHAGECTOMY: RESULTS FROM SEVEN HIGH VOLUME ITALIAN CENTERS
Authors: Voltarel Guerrino , Turolo Cecilia , Collizzolli Alice , Canepari Elia , Ajazi Barbara , De Pasqual Carlo Alberto , Weindelmayer Jacopo , Giacopuzzi Simone 
Published: September 2024

Abstract

Background
Over the past decade, minimally invasive esophagectomy has gained increasing attention, supported by numerous trials and retrospective series highlighting its advantages over the traditional open approach. In addition to the conventional minimally invasive surgery (CMIE), robotic assisted minimally invasive esophagectomy (RAMIE) has gained global popularity, due to its advantages in terms of 3D visualization and instrument stability.

Methods
This is a collaborative study involving seven high-volume Italian centers affiliated with the Italian Society for the Study of Esophageal Diseases (SISME). Patients who underwent Ivor Lewis esophagectomy for esophageal cancer between January 2015 and July 2022 were identified from seven institutional databases and divided in two groups according to the thoracic approach: CMIE versus RAMIE.

Results
We identified 316 patients in CMIE and 123 in RAMIE group. Operative time was significantly longer for RAMIE procedures (p&lt;0.001). A borderline significant reduction in overall complication rate was observed (48% vs 59% in CMIE group, p=0.045), however there were no differences in severe (p=0.3) and pulmonary (p=0.13) complications rate. 90-day mortality (CMIE 3.2% vs RAMIE 0.8%, p=0.15) and readmission rate (CMIE 9.5% vs RAMIE 7.3%, p=0.47) were comparable. R0 rate was 94.9% in CMIE vs 92.7% in RAMIE (p=0.4). The most performed anastomosis was circular stapled anastomosis. Anastomotic leak rate was 13.9% for CMIE and 12.2% for RAMIE (p=0.6).

Conclusion
Minimally invasive Ivor Lewis esophagectomy has reached adequate surgical and oncological results with both conventional and robotic technique. Nowadays there is no clear superiority of one anastomotic technique.
404. REAL-WORLD TREATMENT PATTERN OF EOSINOPHILIC ESOPHAGITIS IN JAPAN
Authors: Sawada Akinari , Ihara Yasutaka , Imai Takumi , Fujiwara Yasuhiro 
Published: September 2024

Abstract

Background
Eosinophilic esophagitis (EoE) is characterized by eosinophilic infiltration in the esophageal epithelium that causes esophageal dysfunction-related symptoms. The treatment for EoE includes acid suppressants (proton pump inhibitors (PPIs) or potassium competitive acid blocker (P-CAB)), topical corticosteroid (TCS), and diet therapy. In addition, biologics (i.e. dupilumab) have been recently approved for EoE in the US. However, the appropriate initial and maintenance therapy for EoE have not been established yet. Therefore, the aim of the study was to investigate the treatment pattern of EoE and its association with fibrostenosis in Japan.

Methods
We investigated prescription pattern for EoE analyzing an employer-based health insurance claim database from 2005 to 2022. EoE cases were identified based on the International Classification of Diseases-tenth Revision code, K20.0. The initial treatment of interest for EoE included PPIs, P-CAB, and TCS (swallowed inhaled CS). The initial treatment for EoE was defined as these drugs prescribed within two months from the index date of EoE diagnosis. The discontinuation rates of initial PPIs or P-CAB were analyzed using Kaplan-Meier method. The discontinuation of treatment was defined as no treatment following within 90 days from the prescription of the previous treatment.

Results
Overall, 984 EoE patients (45 years old [38-52], male 747 [75.9%]) were ultimately analyzed. Most of the initial treatment for EoE was acid suppressants (PPIs [323 54.9%], P-CAB [241, 41%]), followed by TCS (13, 2.2%) and combination therapy of PPIs or P-CAB and TCS (11, 1.9%). PPIs or P-CAB discontinued in approximately 50% and 70% of the cases at approximately 150 days and 720 days respectively from the start of the initial therapy. The switching to the second-line therapy from the initial PPIs or P-CAB rarely happened. During the observation period, no EoE patients developed esophageal stenosis.

Conclusion
PPIs or P-CAB were most prescribed as the initial treatment for EoE in Japan. In addition, more than half of EoE patients discontinued such initial therapy within 2 years without fibrostenotic complication. These findings indicate that EoE that can respond to initial acid suppressants therapy does not necessarily require the maintenance therapy to prevent esophageal fibrostenosis.
435. PREVALENCE OF OESOPHAGEAL PREMALIGNANT LESIONS AMONG PATIENTS REFERRED FOR GASTRO-OESOPHAGEAL-DUODENOSCOPY AT A TERTIARY CARE HOSPITAL IN NORTHERN, SRI LANKA
Authors: Rajasooriyar Ida Chrishanthi , Gobishangar Sreekanthan , Namasivayam Vikneswaran , De Silva Chandu , Amaratunga Priyani , Sarma Sundaramoorthy Iyer Thuraisamy , Thusyanthan Vinayagamoorthi , Kajendran Anuradha , Thanenthiran Antony Joseph , Murugathas Thanuja , Balendran Karthiha , Theepan Jathavani MM , Surenthirakumaran Rajendra 
Published: September 2024

Abstract

Background
Oesophageal cancer is the second leading cause of cancer-related mortality in Sri Lanka, where a higher prevalence is found among Tamil-speaking Sri Lankans. Endoscopic screening with Lugol’s chromo endoscopy in high-incidence populations reduces mortality from oesophageal cancer. The objective of this study is to determine the prevalence of premalignant oesophageal lesions - squamous dysplasia and Barrett’s oesophagus and the associated risk factors among Tamil patients undergoing oesophageal-gastro-duodenoscopy (OGD).

Methods
Consecutive patients undergoing OGD for dyspeptic and gastric acid reflux symptoms were recruited. An interviewer-administered questionnaire was used for data collection. During OGD, the oesophagus was examined under white light imaging, narrow band imaging (NBI), and Lugol’s iodine chromo endoscopy. Biopsies were taken from abnormal mucosa and sent for pathological diagnosis. Statistical software SPSS (V25) was used to analyse the data.

Results
The study incorporates 410 participants. The majority (61.7%) were females and the median age was 57 (Interquartile range 21) years.
On Endoscopy under white light and NBI 11.0%(n=45) had squamous neoplasia. Of them, 16.0% had Low grade dysplasia (LGD), 2.0% had invasive carcinoma and the remaining 82.0% had inflammatory or reactive changes.
Endoscopic Barrett’s oesophagus (BO) was found in 17.0% (n=69) and 5.0% (n=19) had both endoscopic and histological confirmation of BO. Of them, 21.0% had LGD. In regression analysis, male gender was at higher risk for BO (OR- 1.251, 95%CI 0.420 – 3.730).
Overall, 3.0% of the participants had premalignant lesions.

Conclusions
The prevalence of premalignant lesions in a symptomatic population was only 3.0%. Further studies with a larger number of targeted population is needed to assess the exact prevalence.
444. QUALITY OF LIFE OF CHILDREN AFTER ESOPHAGEAL REPLACEMENT
Authors: Sosnova Sofya , Bataev Saidkhassan , Razumovsky Alexander , Alkhasov Abdumanap , Bataev Ali , Feoktistova Elena 
Published: September 2024

Abstract

Introduction
For reconstruction of the esophagus in children colon interposition and reconstruction of the esophagus by stomach should are most often used. This work aims to compare the quality of life of patients in these groups to determine the optimal method for esophageal reconstruction in children.
Material and methods.
For 6 years 167 esophageal replacement was performed at the Filatov Children's Hospital. Of these, 57 children were evaluated for quality of life through a questionnaire, which was carried out when the child was re-admitted for follow-up examinations. All operations were performed by the same team of surgeons. We compiled the questions in the questionnaires specifically for this group of patients, which are shown in the table 1. The questionnaire for children under 14 years of age was completed by parents. Older children 14-year-olds filled out the questionnaire independently.
The respondents were divided into 2 groups. Group 1 – 26 children who underwent reconstruction of the esophagus by stomach. The 2nd group included 29 children after colonic interpositions. In terms of gender, age and indications for surgery were comparable in both groups. Patients were interviewed from 6 months to 5 years after surgery.

Results
Tab. 1 Comparative analysis of results interviewed patients in two groups
Despite the fact that esophageal reconstruction by stomach is easier to perform and it is even possible to perform this operation laparoscopically, as can be seen from the table above, children have significantly more problems in many indicators affecting the quality of life.

Conclusions
Reconstruction of the esophagus by stomach should be used for: reoperations after failed colon interposition; malformations and other pathologies of the colon and the “loose” type of blood supply to the colon. The operation of choice, in our opinion, is colon interposition, which demonstrates the best indicators of quality of life.
452. THE TREATMENT STRATEGY FOR RECURRENT OR UNRESECTABLE ESOPHAGEAL CANCER USING IMMUNE CHECKPOINT INHIBITORS
Authors: Toriumi Tetsuro , Miyawaki Yutaka , Lee Seigi , Kobayashi Ryota , Takabatake Kazuya , Ebara Gen , Sato Hiroshi , Sakuramoto Shinichi 
Published: September 2024

Abstract

Background
Cisplatine+5-FU (CF) was the first regimen for patients with recurrent or unresectable esophageal cancer in Japan. Nevertheless, the efficacy of the treatment was limited, and the prognosis of these patients was very poor. Recently, CF + Pembrolizumab (CF+Pmeb), CF + Nivolumab (CF+Nivo), Ipilimumab + Nivolumab (Ipi+Nivo) regimens were covered by the Japanese national health insurance system, and we get the option to use immune checkpoint inhibitor for advanced esophageal cancer.

Methods
Forty-six patients with recurrent or unresectable esophageal cancer treated with regimens including immune checkpoint inhibitors, were included in this study. We compared best overall response (BOR) among these three regimens. Besides, we also reviewed the validity of conversion surgery.

Results
Of the 46 patients, 17 and 29 patients were treated for recurrent and unresectable esophageal cancer, respectively. Among the patients with unresectable cancer, 3 patients were diagnosed with CR and 3 patients underwent conversion surgery, whose regimens were CF+Pmeb or CF+Nivo. We could achieve R0 resection in all 3 patients with conversion surgery. Postoperative complications grade 2 or more did not occur in these 3 patients. Recurrence has not been observed yet, though the follow-up periods were short (3 to 5 months). Among the patients with recurrence, 2 patients achieved a CR after treatment with CF+immuno checkpoint inhibitor.

Conclusion
Regimens with immune checkpoint inhibitors would be the hopeful treatment for advanced esophageal cancer patients. Conversion surgery would also play an important role in improving the prognosis.
470. INTENSIVE EARLY SURVEILLANCE FOLLOWING ESOPHAGECTOMY IDENTIFIES DISTINCT PATTERNS OF RECURRENCE
Authors: Xiao Karren , Bolger Jarlath , Allison Frances , Darling Gail , Yeung Jonathan 
Published: September 2024

Abstract

Background
There remains a lack of consensus about the protocol for follow-up following esophagectomy. Some centers will utilize a purely radiological approach to follow-up, while others will include routine endoscopy and blood markers. Furthermore, the frequency of follow-up is debated, though many centers will follow-up every 3 months due to the high recurrence rate in the first year. We follow patients every 3 months for the first year, every 6 months for the next year, then yearly to 5 years, solely with CT scans unless symptoms indicate endoscopy. We sought to examine our recurrence rate and survival using this follow-up protocol.

Methods
We reviewed our prospectively collected database for recurrence following esophagectomy in patients operated from March 2018 to May 2022. Consenting patients &gt;18 years of age who underwent esophagectomy were included. Demographics including age, sex, and BMI, tumor factors including pathologic stage, tumor regression grade, and neoadjuvant therapy and post-recurrence treatment data were collected.

Results
We identified 190 patients who underwent esophagectomy and 69 patients had a recurrence. Patients with recurrence were younger (61.3 +/- 10.2 vs 66.4 +/- 10.1, p=0.001), were more likely pT3 (59.4% vs 36.4%, p=0.013) and have a tumor regression grade of 3 (27.5% vs 7.4%, p=0.002). There was no difference between patients with R1 resections vs R0 (5.8% vs 6.6%, p=0.824). Most recurrences were identified on CT scan (95.8%). For patients who recurred within 3 months, the mean time from operation to death was 9.11 months. Patients who recurred between 3-6mo, 6-9mo, and 9-12mo died at 17.1mo, 15.7mo, and 17.5mo following surgery, respectively. Patients who recurred in the next year died around 40 months from surgery.

Conclusion
As with other reports in the literature, recurrence is highest in the first year after esophagectomy. Patients recurring in the first 3 months had a short survival following esophagectomy and may represent missed micrometastatic disease at staging. Interestingly, patients who recurred between 3-12 months all had a similar time to death from the date of operation, suggesting lead-time bias for those detected at 3-6months. Early and later recurrence appear to have distinct biological behaviours. With improved and tailored adjuvant therapies, earlier detection may yet be beneficial and will require further study.
471. MANAGEMENT OF EARLY ESOPHAGEAL CANCER - A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Authors: Campbell Sally , Davey Matthew , Donlon Noel 
Published: September 2024

Abstract

Background and Objectives
Optimal surgical management for early oesophageal cancer remains controversial. We aimed to perform a network meta-analysis (NMA) of studies comparing outcomes after open esophagectomy (OE), minimally invasive esophagectomy (MIE), endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) for early oesophageal cancer.

Methods
A systematic search of electronic databases was undertaken. A network meta-analysis was performed as per PRISMA-NMA guidelines. Statistical analysis was performed using R and Shiny.

Results
21 studies including 10,002 patients with stage Tis, T1a or T1b oesophageal carcinoma were included. Overall, 3,103 patients underwent ESD (31%, 3103/10,002), 6,191 underwent OE (61.9%, 6,191/10,002), 502 underwent EMR (5.2%, 502/10,002) and 206 underwent MIE (2.1%, 206/10,002). At NMA, at approximately 3.5 years follow up, there was a significant difference in recurrence rates of Tis, T1a or T1b disease following OE (odds ratio (OR): 0.32, 95% CI 0.12 – 0.83) as compared to EMR. Compared to ESD, estimated 5 year overall survival for Tis, T1a and T1b disease were equivocal following OE and EMR respectively (OR: 0.98, 95% CI 0.66 – 1.44), (OR: 0.88, 95% CI 0.38-2.04). When compared with ESD, superior resection rate was observed in OE (OR: 4.04 95% CI 2.56, 6.37) and MIE (OR: 16.49, 95% CI 2.19, 123.86). OE had the highest rate of pulmonary complications. Compared with ESD, pulmonary complications were significantly different to those who underwent OE (OR: 4.06, 95% CI 2.28 – 7.22). OE had the highest rate of recurrent laryngeal nerve injury, post operative ileus and procedure specific mortality as compared to ESD, EMR and MIE which was not found to be significantly different at NMA. ESD and EMR exhibited advantages over OE and MIE in certain procedural aspects including procedure duration, length of hospital stay and cost.

Conclusions
OE was associated with superior surgical outcomes compared to ESD. Disease recurrence was also higher in EMR compared to OE with improved cost-effectiveness for ESD and EMR. ESD demonstrated reduce morbidity as compared to OE. Considering these results, OE, MIE, ESR and EMR are all feasible options for primary early oesophageal cancer, contingent on surgeon and institutional expertise.